# EDGAR Filing Document

**Accession Number:** 0000862861
**File Stem:** 0000000000-25-010201
**Filing Date:** 2025-9
**Character Count:** 3521
**Document Hash:** 1a146dde43e965ec43c3ee458dc88db9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010201.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0000000000-25-010201

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250918

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALT5 Sigma Corp
- **CENTRAL INDEX KEY:** 0000862861
- **STANDARD INDUSTRIAL CLASSIFICATION:** [6221]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 411454591
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 000-19621

**BUSINESS ADDRESS:**
- **STREET 1:** 325 E. WARM SPRINGS ROAD
- **STREET 2:** SUITE 102
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89119
- **BUSINESS PHONE:** 702-997-5968

**MAIL ADDRESS:**
- **STREET 1:** 325 E. WARM SPRINGS ROAD
- **STREET 2:** SUITE 102
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JanOne Inc.
- **DATE OF NAME CHANGE:** 20190912

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
- **DATE OF NAME CHANGE:** 19930328
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-25-013104

## Text-Extract

```

                                                           September 18, 2025

Jonathan Hugh
Chief Financial Officer
ALT5 Sigma Corporation
325 E. Warm Springs Road, Suite 102
Las Vegas, Nevada 89119

       Re: ALT5 Sigma Corporation
           Preliminary Proxy Statement on Schedule 14A
           Filed September 12, 2025
           File No. 000-19621
Dear Jonathan Hugh:

       We have reviewed your filing and have the following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

         After reviewing your response and any amendment you may file in
response to this
letter, we may have additional comments.

Preliminary Proxy Statement on Schedule 14A
Proposal 1
The Issuance and Appointment Proposal, page 7

1.     We refer to Proposal 1, which seeks shareholder approval for (i) the
issuance of
       119,000,000 shares of common stock upon the exercise of pre-funded
warrants and
       common stock purchase warrants, and (ii) the appointment of a nominee to
the board
       of directors. Please tell us why these two matters should not be in
separate
       proposals. Refer to Rule 14a-4(a)(3).
2.     We note that the appointment of the director to the board appears to be
an action taken
       with respect to the election of a director. Accordingly, please revise
the proxy to
       include all information required by Items 7 and 8 of Schedule 14A, or
advise.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.
 September 18, 2025
Page 2

       Please contact Jimmy McNamara at 202-551-7349 or Joe McCann at
202-551-6262
with any other questions.

                                                     Sincerely,

                                                     Division of Corporation
Finance
                                                     Office of Life Sciences
cc:   Faith Charles

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._